Jan 14 (Reuters) - VistaGen Therapeutics Inc :
* VISTAGEN ANNOUNCES POSITIVE RESULTS FROM EXPLORATORY PHASE 2A STUDY OF PH284 IN CANCER CACHEXIA
* VISTAGEN ANNOUNCES POSITIVE RESULTS FROM EXPLORATORY PHASE 2A STUDY OF PH284 IN CANCER CACHEXIA
* VISTAGEN THERAPEUTICS INC - PH284 DEMONSTRATES NO SERIOUS ADVERSE EVENTS
* VISTAGEN THERAPEUTICS INC - PHASE 2A STUDY EVALUATES EFFICACY, SAFETY, AND TOLERABILITY OF PH284
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。
没有相关数据
如果下载按钮点击无跳转,请点击右上角菜单选择 “在浏览器打开”